We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
Read MoreHide Full Article
Thermo Fisher Scientific Inc.'s (TMO - Free Report) third-quarter 2019 adjusted earnings per share (EPS) came in at $2.94, beating the Zacks Consensus Estimate by 2.1%. The figure also improved from the year-ago quarterly figure by 12.2%. On a reported basis, EPS was $1.88, up 7.4% year over year.
Revenues in the quarter under review grossed $6.27 billion, up 5.9% year over year. The top line also beat the Zacks Consensus Estimate by 1.3%.
Quarter in Detail
Organic revenues in the reported quarter grew 7% year over year while currency translation affected total revenues by 1%.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.
Revenues at the Life Sciences Solutions segment (27.1% of total revenues) improved 13.3% year over year to $1.70 billion while Analytical Instruments Segment sales (21.7%) edged up 2.3% to $1.36 billion.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Revenues at the Laboratory Products and Services segment (41.8%) rose 6.1% to $2.62 billion. The Specialty Diagnostics segment (14%) recorded a 1.1% drop from the year-ago quarter to $0.88 billion.
Gross margin of 46% during the third quarter contracted 22 basis points (bps) year over year despite a 5.4% rise in gross profits. Adjusted operating margin for the quarter came in at 22.5%, reflecting an expansion of 27 bps.
The company exited the third quarter of 2019 with cash and cash equivalents of $1.27 billion, compared with $2.29 billion in the second quarter. Year to date, net cash provided by operating activities was $3.06 billion compared with $2.74 billion a year ago.
2019 Guidance
Banking on an improvement in operational performance, Thermo Fisher has raised its 2019 revenue and earnings guidance.
Revenue guidance has been raised to $25.34-$25.50 billion from the earlier-provided $25.30-$25.50 billion, indicating revenue growth of 4% to 5% from 2018. The Zacks Consensus Estimate of $25.43 billion is within the guided range.
Adjusted EPS guidance for 2019 has also been raised to $12.28 to $12.34 (previous range was $12.16 to $12.26), suggesting 10% to 11% growth from 2018. The Zacks Consensus Estimate of $12.25 falls below the guided range.
Bottom Line
Thermo Fisher ended the third quarter of 2019 on a solid note with both EPS and revenues beating the Zacks Consensus Estimate. We are encouraged that three of its four business segments witnessed strong year-over-year revenue growth.
During the reported quarter, the company launched a range of products like the TSQ Altis, the Quantis MD mass spectrometers and the Vanquish MD HPLC for clinical diagnostic laboratories. The company also broadened its global market reach by setting up a Biosciences Customer Exploration Center in Shanghai and expanding its clinical trials logistics facility in Suzhou. We are looking forward to the recently-completed acquisition of an active pharmaceutical ingredient manufacturing facility in Cork, Ireland, of GlaxoSmithKline. Meanwhile, adjusted operating loss during the quarter is concerning.
Zacks Rank and Key Picks
Thermo Fisher currently has a Zacks Ranks #3 (Hold).
The Zacks Consensus Estimate for ResMed’s first-quarter fiscal 2020 revenues is pegged at $657.2 million, calling for a year-over-year increase of 11.7%. The same for adjusted EPS stands at 87 cents, indicating an increase of 7.4% from the year-ago reported figure.
The Zacks Consensus Estimate for Syneos’ third-quarter fiscal 2019 revenues is pegged at $1.18 billion, suggesting 6.03% growth from the prior-year reported figure. The same for adjusted earnings per share stands at 72 cents, implying a 5.3% improvement from the year-ago reported number.
The Zacks Consensus Estimate for McKesson’s second-quarter fiscal 2020 revenues is pegged at $54.94 billion, suggesting 3.5% growth from the prior-year reported figure. The same for adjusted EPS stands at $3.59.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
Thermo Fisher Scientific Inc.'s (TMO - Free Report) third-quarter 2019 adjusted earnings per share (EPS) came in at $2.94, beating the Zacks Consensus Estimate by 2.1%. The figure also improved from the year-ago quarterly figure by 12.2%. On a reported basis, EPS was $1.88, up 7.4% year over year.
Revenues in the quarter under review grossed $6.27 billion, up 5.9% year over year. The top line also beat the Zacks Consensus Estimate by 1.3%.
Quarter in Detail
Organic revenues in the reported quarter grew 7% year over year while currency translation affected total revenues by 1%.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.
Revenues at the Life Sciences Solutions segment (27.1% of total revenues) improved 13.3% year over year to $1.70 billion while Analytical Instruments Segment sales (21.7%) edged up 2.3% to $1.36 billion.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
Revenues at the Laboratory Products and Services segment (41.8%) rose 6.1% to $2.62 billion. The Specialty Diagnostics segment (14%) recorded a 1.1% drop from the year-ago quarter to $0.88 billion.
Gross margin of 46% during the third quarter contracted 22 basis points (bps) year over year despite a 5.4% rise in gross profits. Adjusted operating margin for the quarter came in at 22.5%, reflecting an expansion of 27 bps.
The company exited the third quarter of 2019 with cash and cash equivalents of $1.27 billion, compared with $2.29 billion in the second quarter. Year to date, net cash provided by operating activities was $3.06 billion compared with $2.74 billion a year ago.
2019 Guidance
Banking on an improvement in operational performance, Thermo Fisher has raised its 2019 revenue and earnings guidance.
Revenue guidance has been raised to $25.34-$25.50 billion from the earlier-provided $25.30-$25.50 billion, indicating revenue growth of 4% to 5% from 2018. The Zacks Consensus Estimate of $25.43 billion is within the guided range.
Adjusted EPS guidance for 2019 has also been raised to $12.28 to $12.34 (previous range was $12.16 to $12.26), suggesting 10% to 11% growth from 2018. The Zacks Consensus Estimate of $12.25 falls below the guided range.
Bottom Line
Thermo Fisher ended the third quarter of 2019 on a solid note with both EPS and revenues beating the Zacks Consensus Estimate. We are encouraged that three of its four business segments witnessed strong year-over-year revenue growth.
During the reported quarter, the company launched a range of products like the TSQ Altis, the Quantis MD mass spectrometers and the Vanquish MD HPLC for clinical diagnostic laboratories. The company also broadened its global market reach by setting up a Biosciences Customer Exploration Center in Shanghai and expanding its clinical trials logistics facility in Suzhou. We are looking forward to the recently-completed acquisition of an active pharmaceutical ingredient manufacturing facility in Cork, Ireland, of GlaxoSmithKline. Meanwhile, adjusted operating loss during the quarter is concerning.
Zacks Rank and Key Picks
Thermo Fisher currently has a Zacks Ranks #3 (Hold).
A few better-ranked stocks in the broader medical space are Mckesson (MCK - Free Report) , ResMed (RMD - Free Report) and Syneos Health . While ResMed has a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for ResMed’s first-quarter fiscal 2020 revenues is pegged at $657.2 million, calling for a year-over-year increase of 11.7%. The same for adjusted EPS stands at 87 cents, indicating an increase of 7.4% from the year-ago reported figure.
The Zacks Consensus Estimate for Syneos’ third-quarter fiscal 2019 revenues is pegged at $1.18 billion, suggesting 6.03% growth from the prior-year reported figure. The same for adjusted earnings per share stands at 72 cents, implying a 5.3% improvement from the year-ago reported number.
The Zacks Consensus Estimate for McKesson’s second-quarter fiscal 2020 revenues is pegged at $54.94 billion, suggesting 3.5% growth from the prior-year reported figure. The same for adjusted EPS stands at $3.59.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>